Myocardial Infarction: PCI and medications

Primary percutaneous coronary intervention (PCI) serves as the preferred revascularization strategy for acute myocardial infarction, offering superior restoration of coronary blood flow and lower intracranial hemorrhage risks compared to thrombolytic therapy. High-risk patients, including those over 75 or experiencing hemodynamic instability, derive the most significant benefits from timely PCI. Effective post-infarction management integrates essential adjunct therapies like aspirin, beta-blockers, and ACE inhibitors to improve survival and mitigate ventricular remodeling. While complications such as cardiogenic shock and mechanical ruptures necessitate aggressive interventions like intra-aortic balloon pumps and surgical repair, routine prophylactic lidocaine administration is contraindicated due to associated mortality risks. Instead, clinical focus must prioritize maintaining electrolyte homeostasis, particularly potassium and magnesium levels, to prevent arrhythmias and optimize patient outcomes in intensive care settings.